| Literature DB >> 24455729 |
Massimo Origoni1, Marta Parma1, Giacomo Dell'Antonio2, Chiara Gelardi1, Chiara Stefani1, Stefano Salvatore1, Massimo Candiani1.
Abstract
Strong evidence exists that the host's immune system plays a crucial role for the development of human papillomavirus-related cervical premalignant and malignant lesions. In particular, effective cell-mediated immunity (CMI) promotes spontaneous infection clearance and cancer precursors regression in healthy subjects, while immunosuppressed individuals are more likely to experience infection persistence, cervical intraepithelial neoplasia (CIN) lesions, and cervical cancer. In this study, the prognostic significance of immunohistochemical profiling of CD4+ T-cells, CD8+ T-cells, dendritic cells (CD11c+), T-bet+, and GATA-3+ transcription factors has been studied in surgical specimens of 34 consecutive women affected by high-grade cervical intraepithelial neoplasia (CIN2-3) submitted to cervical conization. Results have been correlated with the clinical outcomes at 24 months after treatment and statistically analyzed. Higher rates of CD4+ T-cells, CD11c+ dendritic cells, and T-bet+ transcription factor positivity showed a strong statistically significative correlation with favourable clinical outcomes (P ≤ 0.0001). These data reinforce the evidence of the relevance of the host's immune status in the natural history of HPV-related cervical disease and add a prognostic significance of the cervical immunological profile in terms of predicting significant lower recurrence rates.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24455729 PMCID: PMC3878632 DOI: 10.1155/2013/831907
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1CD4+ T-cells immunohistochemical staining.
Figure 2CD11c+ (dendritic cells) immunohistochemical staining.
Figure 3T-bet+ transcription factor immunohistochemical staining.
Positivity of immunohistochemical targets within the epithelium.
| NED | REC | |||||
|---|---|---|---|---|---|---|
| <5% | >5% | <5% | >5% | Fisher exact | Phi | |
| CD4+ | 6 (27.3%) | 16 (72.7%) | 12 (100%) | 0 (0%) |
| −0.70 |
| CD8+ | 19 (86.4%) | 3 (13.6%) | 10 (83.3%) | 2 (16.7%) | n.s. | 0.04 |
| T-bet+ | 4 (18.2%) | 18 (81.8%) | 12 (100%) | 0 (0%) |
| −0.78 |
| GATA3+ | 22 (100%) | 0 (0%) | 10 (83.3%) | 2 (16.7%) | n.s. | 0.34 |
| CD11c+ | 11 (50%) | 11 (50%) | 10 (83.3%) | 2 (16.7%) | n.s. | 0.22 |
NED: not evidence of disease; REC: recurrence of disease.
Positivity of immunohistochemical targets within the stroma.
| NED | REC | |||||
|---|---|---|---|---|---|---|
| <5% | >5% | <5% | >5% | Fisher exact | Phi | |
| CD4+ | 3 (13.6%) | 19 (86.4%) | 12 (100%) | 0 (0%) |
| −0.83 |
| CD8+ | 13 (59.1%) | 9 (40.9%) | 10 (83.3%) | 2 (16.7%) | n.s. | −0.25 |
| T-bet+ | 3 (13.6%) | 19 (86.4%) | 12 (100%) | 0 (0%) |
| −0.83 |
| GATA3+ | 14 (63.6%) | 8 (36.4%) | 7 (83.3%) | 5 (41.7%) | n.s. | 0.05 |
| CD11c+ | 4 (18.2%) | 18 (81.8%) | 10 (83.3%) | 2 (16.7%) |
| −0.63 |
NED: not evidence of disease; REC: recurrence of disease.